Loading clinical trials...
Loading clinical trials...
A Prospective, Open-labelled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation NSCLC Patients With EGFR19 or 21 Exon Mutation
Conditions
Interventions
Erlotinib
cis-platinum
+1 more
Locations
15
China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Beijing Cancer Hospital
Beijing, China
Chinese PLA General Hospital
Beijing, China
The second people's hospital of Sichuan
Chengdu, China
Fujian Medical University Union Hospital
Fuzhou, China
Sun Yat-Sen University Cancer Center
Guangzhou, China
Start Date
August 1, 2012
Primary Completion Date
October 1, 2020
Completion Date
October 1, 2020
Last Updated
October 20, 2016
NCT07250477
NCT06943820
NCT05713006
NCT05557552
NCT06848426
NCT03386929
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions